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The metabolic differences between B-NHL and primary human B
cells are poorly understood. Among human B-cell non-Hodgkin
lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique
subset that is linked to infection with Kaposi’s sarcoma-associated
herpesvirus (KSHV). We report that the metabolic profiles of pri-
mary B cells are significantly different from that of PEL. Compared
with primary B cells, both aerobic glycolysis and fatty acid synthe-
sis (FAS) are up-regulated in PEL and other types of nonviral B-
NHL. We found that aerobic glycolysis and FAS occur in a PI3K-
dependent manner and appear to be interdependent. PEL over-
express the fatty acid synthesizing enzyme, FASN, and both PEL
and other B-NHL were much more sensitive to the FAS inhibitor,
C75, than primary B cells. Our findings suggest that FASN may be
a unique candidate for molecular targeted therapy against PEL and
other B-NHL.
Kaposi sarcoma-associated herpesvirus | metabolism
Primary effusion lymphoma (PEL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), which has a poor prognosis,
with a median survival time of 6 mo (1). All PEL are infected
with Kaposi sarcoma-associated herpesvirus (KSHV) and, hence,
represent a tightly defined subtype of B-NHL. PEL display ele-
vated levels of activated phosphatidylinositol 3-kinase (PI3K),
AKT, and mammalian target of rapamycin (mTOR) kinases (2,
3). Our group and others have shown that KSHV viral proteins
such as K1 and vGPCR can activate the PI3K/AKT/mTOR
pathway in B lymphocytes and endothelial cells (4–8) and that
the reliance of PEL on the PI3K/AKT/mTOR pathway can be
exploited to treat PEL by using inhibitors of this pathway (2, 3).
Our group has also reported that other types of nonviral B-NHL,
e.g., follicular lymphomas, display activated PI3K/AKT/mTOR
kinases as well (9).
The PI3K/AKT/mTOR signaling pathway is essential for the
control of cell proliferation and protein translation and also
regulates anabolic activities within the cell (10). PI3K/AKT sig-
naling is known to regulate aerobic glycolysis by controlling the
expression and localization of the glucose transporter GLUT1
(11) and expression of glycolytic enzymes (12). PI3K activation
results in PDK1 and subsequently AKT activation, which is
necessary for the induction of glycolytic enzymes (10). The ability
of cancer cells to selectively induce aerobic glycolysis to generate
ATP was first reported by Otto Warburg (13). Glycolysis gen-
erates fewer ATP per molecule of glucose compared with oxi-
dative phosphorylation and produces lactate, which is excreted
(Fig. 1A). Recent studies indicate that up-regulated aerobic
glycolysis in cancer cells exerts a protective effect against apo-
ptosis (14). Moreover, the requirement for high rates of mac-
romolecular synthesis required by rapidly proliferating cancer
cells is met by up-regulating glycolysis (15).
AKT also activates the mTOR signaling complex, which reg-
ulates protein translation. Under nutrient abundant conditions,
mTOR activation stimulates aerobic glycolysis and de novo lipid
synthesis, mediated via mobilization of the SREBP group of
transcription factors (16). SREBP-1 induces the transcription of
fatty acid synthase (FASN), which is a multienzyme complex
responsible for synthesizing cellular lipids. FASN is expressed
in the liver and present at low levels in other tissues. However,
many human cancers express high levels of FASN (17, 18), and
FASN is posited to be a metabolic oncogene (19). Moreover,
aberrant PI3K signaling in cancer cells has been demonstrated to
drive FASN expression via constitutive SREBP-1c activity (20,
21). In this work, we investigated the metabolic sequelae of
PI3K/AKT/mTOR pathway activation on the metabolism of B-
NHL, with a focus on PEL.
Results
PEL Display Elevated Aerobic Glycolysis. To determine the mini-
mum glucose (Glc) requirement of PEL cells, 2 × 105 PEL cells
were cultured in Glc-free media with defined amounts of D-Glc,
and cell survival was monitored by using two independent tech-
niques: trypan blue exclusion (Fig. 1B, Left) and MTS assay (Fig.
1B, Right). Viability of BCP-1, a representative PEL cell line,
decreased when the D-Glc concentration in the growth medium
was lowered, and the reduction in cell viability correlated with
a dose-dependent decrease in Glc concentration (Fig. 1B). These
data were similar in other PEL lines tested, including BC-1,
BCBL-1, BCLM, and VG-1.
Next, 2 × 105 PEL cells were treated with increasing concen-
trations of the glycolytic inhibitor 2-deoxy-D-glucose (2DG), a D-
Glc mimetic that cannot be metabolized by glycolytic enzymes,
thereby inhibiting glycolysis. Cells were cultured in complete
media, which contains 2 mM D-Glc, containing increasing doses
of 2DG for 0, 12, or 24 h and then analyzed by MTS assay. The
proliferation of BCBL-1, a representative PEL, was inhibited in
a dose-responsive manner by 2DG (Fig. 1C), indicating that the
inhibition of glycolysis is sufficient to reduce PEL cell viability.
Intracellular and extracellular levels of Glc and lactate were
measured from primary B lymphocytes isolated from six in-
dividual healthy donors and six different PEL cell lines: BC-1,
BC-3, BCBL-1, BCP-1, JSC-1, and VG-1. Averaged intensities
of intracellular metabolites were normalized to total cellular
protein, and extracellular metabolite intensities were normal-
ized to the total volume of spent media. Compared with pri-
mary B cells, PEL contained lower levels of intracellular Glc
and elevated levels of intracellular lactate (Fig. 2A), indicative
of up-regulated glycolytic flux. Analysis of the spent growth
media from equivalent numbers of cells revealed higher levels
of extracellular lactate and pyruvate in the growth medium of
PEL cells compared with primary B cells (Fig. 2B). PEL media
had a concurrent decrease in extracellular D-Glc, confirming
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enhanced Glc uptake and increased glycolysis in PEL compared
with primary B cells.
We also measured the glycolytic flux of B-NHL and primary B
cells. Cells were pulsed with 10 μCi of D-[5-3H](N)-glucose. [3H]-
H2O generated through glycolysis was measured, and glycolytic
flux was determined by normalizing counts per million to the
total protein input. We first compared PEL to primary B cells
and found that glycolytic flux was significantly increased (P ≤
0.001) up to fourfold in PEL cells compared with primary human
B cells; Fig. 2C shows a representative panel of PEL and primary
B cells. To determine whether heightened glycolysis was a com-
mon feature of other B-NHL, we compared the glycolytic fluxes
of the Burkitt lymphoma (BL) cell line CA46, and the follicular
lymphoma (FL) cell lines K422 and SUDHL4, the PEL lines BC-
1 and BCBL-1, and primary B cells derived from two healthy
donors. Importantly, CA46, K422, and SUDHL4 are EBV- and
KSHV-negative, which allow us to compare PEL to lymphomas
that do not depend on viral infection. Fig. 2D demonstrates that
all B-NHL have an elevated glycolytic flux, whereas primary B
cells consistently have a lower rate of glycolysis compared with all
lymphoma cell lines. These data indicate that despite distinct
etiologies of each of these lymphomas, activation of the Warburg
effect is a common feature among all B-NHL examined.
Up-Regulation of Fatty Acid Synthesis (FAS) in PEL. FASN is a mul-
tifunctional protein complex responsible for synthesizing all cellular
fatty acids. We analyzed equivalent amounts of lysate of PEL cell
lines and primary B cells by immunoblotting to compare the rela-
tive expression of FASN protein. As shown in Fig. 3A, FASN was
highly expressed in every PEL cell line analyzed (Fig. 3A), whereas
FASN expression was barely detectable in lysates from primary B
cells. PEL and primary B cells were also stained with the lipophilic
dye Nile Red and visualized by using fluorescence microscopy (Fig.
S1). PEL cells contain many cytoplasmic lipid droplets that are
absent in primary B cells, indicative of intracellular lipid accumu-
lation. To determine whether FASN protein expression correlated
Fig. 1. Glycolysis and FAS pathways. (A) Once glucose (Glc) enters the cell
through transporters such as GLUT1, hexokinase rapidly phosphorylates Glc
into Glc-6-phosphate, which participates in glycolysis to generate 2 ATP. Py-
ruvate, the end product of glycolysis, is converted into lactate by lactate de-
hydrogenase and is secreted through monocarboxylate transporters (for e.g.,
MCT1). Alternatively, pyruvate can be further oxidized in themitochondrion via
the Krebs cycle to yield 36 ATP per molecule of Glc. Citrate, an intermediate
metabolite, can exit the Krebs cycle and be transported into the cytoplasm,
where it can be broken down into acetyl-CoA. Acetyl-CoA is converted into
malonyl-CoA by acetyl-CoA carboxylase, which is the commitment step of FAS.
Acetyl- and malonyl-CoA, in a series of reactions, are combined by FASN,
a multienzyme polypeptide, to yield palmitate (C16), which is then elongated
or desaturated into other fatty acids. These fatty acids can be used to further
synthesize other macromolecules and lipids necessary for dividing cells. (B)
BCP-1, a representative PEL, is sensitive to Glc deprivation from growth me-
dium, which normally has 2 mM glucose. Reduction of Glc concentration in
growthmedium increases the percentage of dead cells, as visualized by trypan
blue exclusion (Left) and reduces BCP-1 proliferation as determined by MTS
assay (Right). (C) BCBL-1, another representative PEL, is susceptible to 2DG in
a dose-dependent manner. Error bars are ± SEM, and data are representative
of multiple independent experiments. Fig. 2. PEL up-regulate glycolysis. The protein-normalized relative in-
tensities (“scaled intensities”) of intra- and extracellular concentrations of
glycolytic intermediates, represented as box and whisker plots, are signifi-
cantly different between PEL and primary B cells. Data are the combined
average of six different primary B cells derived from six healthy donors and
six PEL lines. (A) Intracellular levels of free Glc are lower, whereas that of
lactate are higher in PEL, compared with primary B cells. (B) The spent media
of PEL contains lower concentration of Glc and increased levels of lactate
and pyruvate compared with the spent media of primary B cells. (C) Equal
numbers of PEL and primary cells were cultured for 24 h, and glycolytic flux
was measured. PEL cells exhibit significantly increased (P = 0.000000026)
glycolysis compared with primary human B cells. (D) Equal numbers of PEL,
BL (CA46), FL (K422 and SUDHL4), and primary B cells were cultured for 24 h,
and glycolytic flux was measured. All B-NHL have significantly (P = 0.000627)
higher glycolytic flux compared with primary B cells. Data are normalized to
total input protein. Error bars are ± SEM; data are one representative of
more than five independent experiments.









with activation of FAS, we determined the rate at which de novo
FAS occurs in PEL and primary B cells by measuring the degree of
incorporation of radiolabeled Glc into the cellular lipid fraction.
Radioactive counts from the extracted lipid fraction of each cell
type were normalized to the total protein content of the cell pellet.
We found that PEL synthesize fatty acids from Glc at a sub-
stantially higher rate (P= 0.012) compared with primary cells (Fig.
3B). Our findings extend to other B-NHL, because similar to PEL,
the FAS rates of CA46, K422, and SUDHL4 were significantly
(P = 0.02) higher than primary B cells (Fig. 3C).
Increased levels of lipid in PEL compared with primary B cells
could be a consequence of either reduced catabolism of lipids or
increased FAS. We therefore measured the rate of fatty acid
oxidation (FAO). Fig. S2 demonstrates that FAO rates are not
significantly different between PEL and primary B cells. Thus,
FAS seems to be the dominant fatty acid metabolic pathway up-
regulated in PEL.
To establish the importance of increased FAS for B-NHL sur-
vival, we inhibited FAS with C75, a FASN inhibitor (22). When
treated with increasing doses of C75, all B-NHL cells displayed
a dose-dependent increase in cell death, as measured by trypan
blue exclusion. In Fig. 3D, BC-1 and BC-3 are shown as repre-
sentative PEL. Fig. S3 A and B respectively demonstrate that both
CA46 and SUDHL4 are susceptible to C75, however, the degree
of susceptibility is not as great as that of PEL. FAS inhibition by
C75 resulted in activation of proapoptotic caspase-3 in all B-NHL
(Fig. S3C). In contrast, primary B cells were minimally affected by
C75 (Fig. 3E). Thus, the susceptibility of these B-NHL lines to
C75, while sparing primary B cells, reveals FAS as a unique target
for molecular targeted therapy in B-NHL.
B lymphocytes isolated from the peripheral blood are nor-
mally in a resting state. PEL are lymphoma cells and, hence,
proliferate continuously in the absence of specific stimulus. To
rule out the possibility that differentials in glycolysis and FAS
were a consequence of proliferation rather than the trans-
formed phenotype, we measured glycolytic flux, FAS rates, and
FASN expression in activated primary B cells. Primary B cells
were treated for 48 h with either PBS as vehicle or 10 μg/mL
lipopolysaccharide (LPS) to stimulate B-cell proliferation as
reported (23), after which proliferation was confirmed by using
the MTS assay (Fig. 4A), and live cell counts were measured by
trypan blue exclusion (Fig. S4C). The rates of glycolysis (Fig.
4B) and lipid synthesis (Fig. 4C) were quantified and compared
with PEL (BC-1 and BCBL-1). LPS-stimulated B cells pro-
liferated more than unstimulated B cells, as expected (Fig. 4A
and Fig. S4C, Right). Despite the elevated glycolytic rate of
stimulated primary B cells, their rate of glycolysis was still
significantly lower (P ≤ 0.01) than that of vehicle-treated PEL
cells (Fig. 4B). Interestingly, FAS did not substantially change
in LPS-stimulated versus vehicle-treated primary B cells (Fig.
4C). However, both these rates of FAS were significantly lower
than that of an equivalent number of vehicle-treated BC-1 and
BCBL-1 PEL cells (P ≤ 0.05). LPS stimulation of PEL did not
further increase glycolysis or FAS compared with vehicle-
treated PEL (Fig. S4 A and B), and PEL proliferation was not
altered by LPS treatment, unlike primary B cells that did
Fig. 3. FAS is a critical and essential metabolic pathway for the proliferation
of PEL. (A) PEL express higher levels of FASN compared with primary B cells.
Ku80 is shown as a loading control. (B) The rate of FAS in PEL is significantly
higher (P = 0.012) compared with primary B cells. (C) PEL (BC-1 and BCBL-1)
have higher FAS rates compared with BL (CA46) and FL (K422 and SUDHL4).
Collectively, all B-NHL have a higher FAS rate compared with primary B cells.
Data are normalized to total input protein and is one representative of
multiple independent experiments. Error bars are ± SEM. (D) Inhibition of
FAS using varying concentrations of the FASN inhibitor, C75, leads to a dose-
dependent increase in cell death in BC-1 (Left) and BC-3 (Right) PEL cells, as
measured by trypan blue exclusion. (E) Inhibition of FAS using C75 leads to
minimal cell death in primary B cells from two donors, as measured by trypan
blue exclusion. Error bars are ± SEM.
Fig. 4. LPS-driven proliferation of primary B cells is not linked to the rate
of FAS as is evident in untreated PEL. (A) Stimulation of primary B cells with
10 μg/mL LPS leads to an increase in proliferation as measured by MTS
assay. (B) Glycolysis is minimally up-regulated in LPS-stimulated pro-
liferating primary B cells, but the rates are significantly lower (*P ≤ 0.05)
than those of vehicle-treated PEL. (C) FAS is not up-regulated in LPS-
stimulated primary B cells and the rates of FAS are significantly lower (*P ≤
0.01) than those seen in untreated PEL. Error bars are ± SEM. (D) There is
a slight increase in FASN expression in LPS-stimulated proliferating primary
B cells, but these levels are 5 times lower than that seen in untreated PEL
(quantified using densitometry). Ku80 is a loading control.
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proliferate in response to LPS stimulation (Fig. S4C, Left).
Furthermore, immunoblot analysis of cell lysates revealed that
FASN expression in primary B cells was slightly increased upon
LPS stimulation (Fig. 4D), which was still fivefold lower than that
of unstimulated (vehicle-treated) PEL cells. These data potentially
suggest that FASN activity is an independent phenotype of PEL
rather than a consequence of increased proliferation index and
that up-regulated lipid synthesis is a metabolic signature of PEL.
PEL Have a Distinct Lipid Synthesis Profile Compared with Primary B
Cells.We identified the major classes of lipids resulting from FAS
by culturing primary B and PEL cells in medium supplemented
with D-[U-14C6]-Glc (24). Table S1 demonstrates that PEL and
primary B cells have different amounts of de novo synthesized
lipids that are derived from Glc. We found that the major com-
ponents of eukaryotic cell walls, e.g., phosphatidylcholine and
phosphatidylethanolamine, are preferentially and abundantly syn-
thesized by PEL compared to primary B cells. The ratio of de
novo lipids and triglycerides synthesized by using glucose pre-
cursors is much higher in PEL compared with primary B cells.
Glycolysis and FAS Are Intimately Linked in B-NHL. We measured
both glycolytic flux and rates of FAS in an equivalent number
of both PEL and primary B cells, in the presence of 1 mM
2DG (glycolysis inhibitor), or 10 μg/mL C75 (FASN inhibitor) for
72 h. As shown in Fig. 5A, 2DG inhibited glycolysis in both cell
types, as expected. However, C75 also reduced glycolysis to
levels similar to that seen after 2DG treatment (Fig. 5A). In the
converse experiment, Fig. 5B demonstrates that while C75 ex-
pectedly and potently inhibits FAS, 2DG also reduced FAS in
PEL, suggesting that upregulated glycolysis is a mechanism for
generating intermediates for fatty acid synthesis (15, 25). In
contrast, the rate of FAS in primary B cells remained static and
independent of 2DG treatment (Fig. 5B). In PEL, inhibition of
FAS decreased the rate of glycoysis and conversely, glycolysis
inhibition blocked FAS, demonstrating that both glycolysis and
FAS are intimately linked, with inhibition of one pathway
impacting the other. Moreover, these two pathways are linked in
other B-NHL subsets as well. Fig. 5C demonstrates that FAS
inhibition reduces glycolytic flux in the FL cell lines, K422 and
SUDHL4, and an EBV-positive lymphoblastoid cell line (LCL).
Conversely, Fig. 5D indicates that glycolysis inhibition potently
reduces FAS in the B-NHL and LCL lines.
Thirty-nine glycolysis and FAS intermediates (listed in Table
S2) from five PEL cell lines and six primary B-cell samples were
analyzed, and the data were subjected to unsupervised clustering
(Fig. 5E) and principal component analysis (PCA) (Fig. 5F).
PEL and primary B cells clearly segregated into two distinct
groups as represented in the dendrogram (Fig. 5E) or along
component 2 in the PCA (Fig. 5F). The dissimilarity between the
PEL cluster and the primary B-cell cluster was much greater than
among primary B-cell cultures alone or among the PEL alone.
Fig. 5. Glycolysis and FAS
are intimately linked in
B-NHL. (A) PEL and primary
B cells treated for 72 h with
10 μg/mL C75 show a signif-
icant decrease in glycolysis
(P ≤ 0.05 for all compar-
isons), similar to 1 mM 2DG-
treated cells (positive con-
trol). Error bars are ± SEM.
(B) PEL cells treated for 72 h
with 1 mM 2DG have de-
creased FAS (P ≤ 0.05), and
with 10 μg/mL C75 (positive
control) have significantly
decreased FAS (P ≤ 0.05).
Primary B cells display min-
imal FAS activity, which is
not down-regulated with
inhibitors. Error bars are ±
SEM; data are representa-
tive of more than three in-
dependent experiments. (C)
B-NHL (including PEL), LCL,
and primary B cells treated
for 72 h with 10 μg/mL C75
show a reduction in glycol-
ysis comparable with 2DG-
treated cells. (D) Glycolysis
inhibition of B-NHL (in-
cluding PEL) and LCL with
2DG substantially reduces
FAS to a rate similar to
the FASN inhibitor C75, but
does not impact FAS in
primary B cells. (E and F) A
dendrogram of hierarchical
clustering (E) and principal
component analysis (F )
of relative intensities of
metabolic intermediates of
glycolysis and FAS demon-
strates that PEL and pri-
mary B cells display distinct
metabolic profiles.









PI3K/AKT Is Required for Increased Glycolysis and FAS in PEL. PI3K/
AKT signaling is known to regulate glycolysis, and a previous
report indicated that PI3K inhibition reduces glycolytic flux and
induces cell cycle arrest in diffuse large B-cell lymphomas (26).
We investigated whether inhibiting PI3K using LY294002 would
alter glycolysis and FAS in PEL. We first determined a dose of
LY294002 (1 μM) that was not significantly cytotoxic to PEL
cell lines over the course of 72 h (Fig. S5). Equivalent numbers
of PEL and primary B cells were treated with either 1 μM
LY294002 or DMSO for 72 h, after which the rates of glycolysis
and FAS were measured as described above. As expected,
LY294002 dramatically (P ≤ 0.01) reduced the glycolytic flux in
both PEL and primary B cells (Fig. 6A). We also found that
LY294002 significantly (P ≤ 0.01) decreased the rates at which
PEL cells incorporated radiolabeled Glc into lipids via FAS (Fig.
6B). However, primary B cells were unaffected (Fig. 6B).
Moreover, as shown in Fig. 6C, LY294002 treatment resulted in
a dose-dependent reduction of FASN expression in PEL, pro-
viding a potential mechanism for the dramatic reduction in FAS
in PEL upon PI3K inhibition. Collectively, these data indicate
that not only does PI3K/AKT inhibition in PEL decrease FASN
expression, but it also diminishes glycolytic flux, thereby pre-
venting Glc incorporation into newly synthesized fatty acids.
FAS Inhibition Leads to an Accumulation of Carnitine. The overall
levels of free carnitine are lower in PEL compared with primary
B cells (Fig. S6A). All data are normalized to protein content
and are shown in Fig. S6. Lowered carnitine levels in colon
cancer cells have been shown to inhibit the generation of apo-
ptosis-inducing O2
− radicals (27). Treatment of PEL and primary
B cells with the FAS inhibitor, C75, resulted in a decrease in
cellular-free carnitine in both cell types; however, the magnitude
of reduction was greater in PEL (31% reduction) compared with
primary B cells (13.5% reduction), which might reflect the fact
that PEL are more sensitive to C75 than primary B cells.
We also measured the relative levels of distinct acyl-carnitine
intermediates by MS. We found that many of the even-chained
acyl-carnitines were increased in PEL compared with primary B
cells (Fig. S6 B and C), which may indicate incomplete oxidation
of fatty acids (28). In contrast, primary B cells display higher
amounts of C3 and C5 acyl-carnitines, which may suggest a re-
liance on oxidation of amino acids rather than fatty acids (28).
Combination of LY294002 and C75 Is Most Effective at Inhibiting PEL
Proliferation. Overall, our findings suggest that FAS is up-reg-
ulated in PEL and other B-NHL. The above experiments in-
dicate that the PI3K inhibitor, LY294002, blocks glycolysis
and FAS in PEL (Fig. 6). Therefore, we sought to determine
whether a combination of LY294002 and C75 would enhance
PEL cell death. We treated PEL cells with increasing doses of
LY294002 and C75 for 72 h and measured cell survival by
trypan blue exclusion. As seen in Fig. S7, either drug alone
reduced cell viability in a dose-dependent manner. However,
combined treatment with 10 μM LY294002 and 10 μg/mL C75
led to death of ∼75% of PEL cells (P ≤ 0.05) in culture. These
data confirm that FAS inhibition may be an efficacious treat-
ment modality for PEL and could be combined with existing
PI3K-targeted chemotherapeutics.
Discussion
We report that B-NHL demonstrate activation of the Warburg
effect, evident in their increased glycolytic activity, even under
normoxic culture conditions. In this paper, we focused on PEL as
a subset of B-NHL. In particular, KSHV-infected PEL are highly
sensitive to Glc withdrawal and the glycolysis inhibitor, 2DG.
Lactate, a byproduct of glycolysis, is present in high levels in the
growth media of PEL. Our flux measurements confirm up-reg-
ulated rates of glycolysis in all B-NHL cells examined, including
PEL, compared with primary B cells from healthy donors. Ad-
ditionally, KSHV infection of endothelial cells was previously
reported to increase glycolysis (29).
We also found that B-NHL actively synthesize fatty acids from
glucose. Enhanced FAS in PEL can at least partly be attributed to
the overexpression of FASN, whereas FASN expression or bio-
synthetic activity in human primary B cells was barely detectable.
These data suggest that aberrant FAS activation may be a meta-
bolic adaptation of PEL and B-NHL. We report that FAS in-
hibition by C75 reduced the viability of B-NHL, whereas primary
B cells remain largely unaffected. Moreover, C75 also sensitized
PEL cells to the PI3K inhibitor LY294002. Susceptibility to FAS
inhibition may arise due to oncogene addiction, a phenomenon
where cancer cells are highly sensitive to inactivation of a pathway
that they depend upon for survival and proliferation (30). Our
data indicate that up-regulated FAS is a characteristic shared by
B-NHL of differing etiologies, and this exquisite dependence on
FAS presents an opportunity to use molecular targeted therapy
selectively against B-NHL, while sparing primary B cells.
Elevated FAS in PEL contributes to an abundance of de novo
synthesized, Glc-derived triglycerides and phospholipids, suggest-
ing that newly generated fatty acids are rapidly incorporated into
membrane lipids and triglyceride stores to accommodate the dra-
matic proliferative rates of lymphoma cells. It is important to note
that FAS precursors can also be generated by other biochemical
pathways such as glutamine metabolism. However, their relevance
in the context of B-NHL remains to be determined.
We report that glycolysis and FAS are intertwined in PEL and
other B-NHL because inhibition of glycolysis affected FAS and
vice versa. The fact that inhibition of glycolysis causes a reduction
in FAS suggests that glycolysis fuels the synthesis of fatty acids in
PEL and B-NHL by providing acetyl-coA intermediates. Con-
versely, FAS inhibition may result in decreased glycolysis, if there
Fig. 6. PI3K inhibition decreases FAS and glycolysis in PEL cells. (A) Treat-
ment of cells for 72 h with a noncytotoxic dose (1 μM) of LY294002 reduces
the rate of glycolysis in both PEL (P ≤ 0.01) and primary B cells (P ≤ 0.01).
Error bars are ± SEM. (B) LY294002 treatment significantly reduces FAS in
PEL (P ≤ 0.01) but does not alter the already low rate of FAS in primary B
cells. Error bars are ± SEM. (C) Treatment with LY294002 leads to a dose-
dependent decrease in expression of FASN in BCBL-1 (Left), BC-3 (Right), and
VG-1 (Center) PEL cells, with a concurrent decrease in pAKT.
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is a feedback loop within the cells whereby decreased FASN
biosynthetic activity leads to a decrease in the generation of
glycolytic intermediates required to fuel FAS.
Fatty acids are essential for subsequent synthesis of macro-
molecules and cell membranes, both of which are necessary for
rapidly dividing cancer cells. Interestingly, primary B cells stimu-
lated to proliferate with LPS up-regulated glycolysis, along with
a concurrent expression of FASN; however, in proliferating pri-
mary B cells, the rate of neither pathway was comparable to the
high degree of glycolysis and FAS taking place in untreated PEL.
These data suggest that enhanced FAS and up-regulated FASN
expression is an advantageous metabolic adaptation of PEL and
other B-NHL. PI3K/AKT pathway activation in PEL contributes to
the increase in both glycolysis and FAS, because treatment of PEL
with a noncytotoxic dose of the PI3K inhibitor, LY294002, reduced
the rate of glycolysis and FASN expression, thus diminishing the
rate of FAS. However, in primary B cells, LY294002 decreased
glycolytic flux, but did not appear to affect the rate of FAS.
Collectively, our data suggest that hyperactivated FAS is es-
sential for the growth advantage of B-NHL. Further, these data
indicate that targeting FASN may be an efficacious therapeutic
strategy for B-NHL.
Materials and Methods
Detailed methods and supporting figures are available in SI Materials
and Methods.
Cell Isolation and Culture. Primary B cells were isolated by negative selection
from donor buffy coats using the B-cell isolation kit II (Miltenyi). Cell lines were
cultured in identical media and culture conditions as described (9, 31, 32).
Cell Viability Assays and Immunoblotting. Proliferation was measured by using
the Cell Titer 96AQueous One Solution (Promega), and apoptosis was
measured by using the ApoAlert Caspase-3 assay (Clontech). Immunoblotting
was performed as described (3).
Measurement of Glycolytic Flux, Lipid Synthesis, and Analysis of Newly
Synthesized Lipids. Glycolytic flux (33) and lipid synthesis (34) were mea-
sured as described. Analysis of lipid components was performed by using
described methods (24). All data were analyzed by using a two-tailed type II
Student’s t test for significance; P values are indicated at appropriate loca-
tions within figure legends.
Metabolic Profiling.Metabolic profiling, peak identification, and curationwas
performed by Metabolon using described methods (35).
Bioinformatics. Hierarchical clustering and principal component analysis was
conducted by using the R programming environment (version 2.13.2)
package FactoMineR.
ACKNOWLEDGMENTS. We thank Edward D. Karoly and Robert Mohney at
Metabolon for metabolomics analysis, the University of North Carolina-
Nutrition and Obesity Research Center for lipid profiling and analysis
(National Institutes of Health Grant DK056350), members of the Damania
and Dittmer labs for helpful discussions, and Marc S. Weinberg for critical
manuscript reading. A.P.B. was supported by training Grants T32-AI007419
and T32-CA071341, and S.R.J. was supported by training Grants T32-CA09156
and T32AI007151. B.D. is supported by CA096500, D.P.D. by DE018304, and
both B.D. and D.P.D. are supported by CA163217 and supplemental funding
from National Cancer Institute to University of North Carolina Lineberger
Comprehensive Cancer Center and Centers for AIDS Research. A.J.F. and L.M.
are supported by AA017376, ES019472, and P30DK034987 and the University
of North Carolina University Cancer Research Fund. J.C.R. is supported
by CA123350. B.D. is a Leukemia and Lymphoma Society Scholar and
a Burroughs Wellcome Fund Investigator in Infectious Disease.
1. Boulanger E, et al. (2005) Prognostic factors and outcome of human herpesvirus 8-
associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23:
4372–4380.
2. Sin SH, et al. (2007) Rapamycin is efficacious against primary effusion lymphoma (PEL)
cell lines in vivo by inhibiting autocrine signaling. Blood 109:2165–2173.
3. Bhatt AP, et al. (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and
paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115:
4455–4463.
4. Wang L, et al. (2004) The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) K1
protein induces expression of angiogenic and invasion factors. Cancer Res 64:
2774–2781.
5. Tomlinson CC, Damania B (2004) The K1 protein of Kaposi’s sarcoma-associated
herpesvirus activates the Akt signaling pathway. J Virol 78:1918–1927.
6. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006) Immortalization of
primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvi-
rus. Cancer Res 66:3658–3666.
7. SodhiA, et al. (2004)Aktplays a central role in sarcomagenesis inducedbyKaposi’s sarcoma
herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 101:4821–4826.
8. Bais C, et al. (2003) Kaposi’s sarcoma associated herpesvirus G protein-coupled re-
ceptor immortalizes human endothelial cells by activation of the VEGF receptor-2/
KDR. Cancer Cell 3:131–143.
9. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B (2010) The dual PI3K/mTOR
inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 24:
1781–1784.
10. Manning BD, Cantley LC (2007) AKT/PKB signaling: Navigating downstream. Cell 129:
1261–1274.
11. Wieman HL, Wofford JA, Rathmell JC (2007) Cytokine stimulation promotes glucose
uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and traf-
ficking. Mol Biol Cell 18:1437–1446.
12. Elstrom RL, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:
3892–3899.
13. Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270.
14. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:
703–707.
15. Young CD, Anderson SM (2008) Sugar and fat - that’s where it’s at: Metabolic changes
in tumors. Breast Cancer Res 10:202.
16. Düvel K, et al. (2010) Activation of a metabolic gene regulatory network downstream
of mTOR complex 1. Mol Cell 39:171–183.
17. Kuhajda FP (2000) Fatty-acid synthase and human cancer: New perspectives on its role
in tumor biology. Nutrition 16:202–208.
18. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA (2008) Overexpression
of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human
breast epithelial cells. Cell Prolif 41:59–85.
19. Flavin R, Peluso S, Nguyen PL, Loda M (2010) Fatty acid synthase as a potential
therapeutic target in cancer. Future Oncol 6:551–562.
20. Yoon S, et al. (2007) Up-regulation of acetyl-CoA carboxylase alpha and fatty acid
synthase by human epidermal growth factor receptor 2 at the translational level in
breast cancer cells. J Biol Chem 282:26122–26131.
21. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid syn-
thesis during neoplastic transformation: Role of mitogen-activated protein kinase
and phosphatidylinositol 3-kinase. Exp Cell Res 279:80–90.
22. Kuhajda FP, et al. (2000) Synthesis and antitumor activity of an inhibitor of fatty acid
synthase. Proc Natl Acad Sci USA 97:3450–3454.
23. Armerding D, Sachs DH, Katz DH (1974) Activation of T and B lymphocytes in vitro. III.
Presence of Ia determinants on allogeneic effect factor. J Exp Med 140:1717–1722.
24. Teng YW, Mehedint MG, Garrow TA, Zeisel SH (2011) Deletion of betaine-homo-
cysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, re-
sulting in fatty liver and hepatocellular carcinomas. J Biol Chem 286:36258–36267.
25. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg
effect: The metabolic requirements of cell proliferation. Science 324:1029–1033.
26. Faber AC, et al. (2006) Inhibition of phosphatidylinositol 3-kinase-mediated glucose
metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large
B-cell lymphomas. Biochem Pharmacol 72:1246–1256.
27. Wenzel U, Nickel A, Daniel H (2005) Increased carnitine-dependent fatty acid uptake
into mitochondria of human colon cancer cells induces apoptosis. J Nutr 135:1510–1514.
28. Newgard CB, et al. (2009) A branched-chain amino acid-related metabolic signature
that differentiates obese and lean humans and contributes to insulin resistance. Cell
Metab 9:311–326.
29. Delgado T, et al. (2010) Induction of the Warburg effect by Kaposi’s sarcoma her-
pesvirus is required for the maintenance of latently infected endothelial cells. Proc
Natl Acad Sci USA 107:10696–10701.
30. Weinstein IB, Joe AK (2006) Mechanisms of disease: Oncogene addiction—a rationale
for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457.
31. Roy D, Dittmer DP (2011) Phosphatase and tensin homolog on chromosome 10 is
phosphorylated in primary effusion lymphoma and Kaposi’s sarcoma. Am J Pathol
179:2108–2119.
32. Roskrow MA, et al. (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for
the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood 91:
2925–2934.
33. Rathmell JC, Farkash EA, Gao W, Thompson CB (2001) IL-7 enhances the survival and
maintains the size of naive T cells. J Immunol 167:6869–6876.
34. Deberardinis RJ, Lum JJ, Thompson CB (2006) Phosphatidylinositol 3-kinase-de-
pendent modulation of carnitine palmitoyltransferase 1A expression regulates lipid
metabolism during hematopoietic cell growth. J Biol Chem 281:37372–37380.
35. Reitman ZJ, et al. (2011) Profiling the effects of isocitrate dehydrogenase 1
and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108:
3270–3275.
Bhatt et al. PNAS | July 17, 2012 | vol. 109 | no. 29 | 11823
M
IC
RO
BI
O
LO
G
Y
